The Bristol-Myers Squibb Lecture
Tuesday, January 10, 2012 at 3:30pm
Room 501 NW Corner
(Refreshments will be provided at 3:00pm prior to the seminar in the Miller Seminar Room 328 Havemeyer)
"The Discovery of BMS-650032; An NS3 Protease Inhibitor for the treatment of Hepatitis C"
Paul Scola
Bristol-Myers
Squibb Research and Development
Wallingford,
CT 06492
Paul.Scola@bms.com
Hepatitis C Virus (HCV) infection is an insidious liver disease that affects more than 170 million people worldwide. The HCV NS3/4A protease is an essential enzyme for viral replication and, as such, has been validated as a target for anti-HCV therapy in clinical trials. In this presentation, the discovery of BMS-650032, a potent and selective inhibitor of the NS3/4A enzyme, presently in clinical trials, will be described. Highlights of this discovery process include the design of the acylsulfonamide chemotype, as well as optimization of ADME and toxicology properties within this chemical series.
"Natural Products, Synthetic Catalysts, Unnatural Products"
Scott Miller
Department of
Chemistry
Yale University
New Haven, Connecticut 06520-8107
scott.miller@yale.edu
Natural products have provided perennial inspiration for the development of synthetic methods, and enzymes have provided an analogous platform for the consideration of catalysis. This lecture will recount an interplay of experiments stimulated by these two major classes of naturally occurring substances. Specifically, the discovery and use of peptides as catalysts for a variety of asymmetric bond formations will be presented. Likewise, applications of these catalysts to the synthesis and selective modification of complex molecules, including biologically active natural products, will be described. A particular emphasis will be placed on reactions that present unusual stereochemical challenges.
Hosted by James Leighton